Algeta to Present New Preclinical Data on Cancer-Killing Effect of Alpharadin (radium-223) at AACR
OSLO, Norway, April 11, 2008 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, will present new data on the cell-killing effect of alpha particle radiation as a radiotherapeutic approach at the American Association for Cancer Research (AACR) Annual meeting in San Diego, CA, USA, being held April 12-16, 2008.
Alpharadin(tm), Algeta's lead product candidate, is a novel bone-seeking radiopharmaceutical based on the alpha particle emitter radium-223 and is being developed as a new treatment for skeletal metastases in patients with late-stage, hormone-refractory prostate cancer.
The data to be presented at AACR increase the understanding of how alpha particles from radium-223 in Alpharadin kill cancer cells by examining their effect on cell survival and cell cycle arrest in different types of tumor cells, as well as their cytotoxic effects in drug-resistant cancer cells.
The schedule for the session, together with the abstract information, is listed below:
Date & Time: 16 April 2008; 08:00 - 12:00 Location: Hall B-F, Poster Section 33, Poster board 1 Poster Session Category: Radiation: Combined Modalities, Cell Death, Bystander Killing and Vascular Effects Abstract Number: 5749 Title: Cellular effects of alpha particle radiation from radium-223: Alpharadin(tm), a new radiopharmaceutical for the treatment of skeletal metastases. Authors: Michael Dornish, Helene Heier-Baardson, Erik O. Pettersen. Algeta ASA, Oslo, Norway, Dept. of Physics, University of Oslo, Oslo, Norway
###
For further information, please contact
Dr. Thomas Ramdahl, CEO Dr. Michael Dornish, CSO +47 23 00 79 90 / +47 913 91 458 (mob) post@algeta.com Dr. Mark Swallow / David Dible Citigate Dewe Rogerson +44 (0)207 638 9571 mark.swallow@citigatedr.co.uk
About Algeta Algeta ASA is a Norwegian cancer therapeutics company built on world-leading, proprietary technology. Algeta is developing new, targeted cancer therapeutics that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use. Algeta's lead product candidate, Alpharadin, is planned to enter Phase III clinical trials in hormone refractory prostate cancer before mid 2008 based on positive Phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers. Algeta is also developing other technologies for delivering alpha emitters. These include microparticles, liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statement
This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products.
Mark Swallow, Ph.D. Citigate Dewe Rogerson
+44 (0)20 7282 2948 (direct) +44 (0)7903 737703 (mobile) +44 (0)20 7638 9571 (switchboard) +44 (0)20 7282 2811 (fax) 3 London Wall Buildings London Wall London EC2M 5SY UK www.citigatedr.co.uk <http://www.citigatedr.co.uk/pharma_biotech.html>
> Huntsworth plc or any of its subsidiary companies may not be held responsible for the content of this email as it may reflect the personal view of the sender and not that of the company. Should you receive this email in error, please notify the sender immediately and do not disclose, copy or distribute it. While Huntsworth plc runs anti-virus software on all servers and all workstations, it cannot be held responsible for any infected files that you may receive. Huntsworth plc advises all recipients to virus scan any file attachments. >
Posted: April 2008
